{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:26:55Z","timestamp":1761128815431},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/inf.0b013e3181d285ac","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T09:38:32Z","timestamp":1268905112000},"page":"563-566","source":"Crossref","is-referenced-by-count":6,"title":["LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS"],"prefix":"10.1097","volume":"29","author":[{"given":"Claudia","family":"Palladino","sequence":"first","affiliation":[]},{"given":"Ver\u00f3nica","family":"Briz","sequence":"additional","affiliation":[]},{"given":"Sergio Negre","family":"Policarpo","sequence":"additional","affiliation":[]},{"given":"Laura Fernandez","family":"Silveira","sequence":"additional","affiliation":[]},{"given":"M Isabel","family":"de Jos\u00e9","sequence":"additional","affiliation":[]},{"given":"M Isabel","family":"Gonz\u00e1lez-Tom\u00e9","sequence":"additional","affiliation":[]},{"given":"David","family":"Moreno","sequence":"additional","affiliation":[]},{"given":"Juan A.","family":"Le\u00f3n Leal","sequence":"additional","affiliation":[]},{"given":"M Jos\u00e9","family":"Mellado","sequence":"additional","affiliation":[]},{"given":"Santiago J.","family":"de Ory","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 T.","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"M \u00c1ngeles","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-21-20210202","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R3-21-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200401010-00003","article-title":"The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.","volume":"35","author":"Rodriguez-French","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-21-20210202","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.clinthera.2006.05.011","article-title":"Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir\/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.","volume":"28","author":"Gathe","year":"2006","journal-title":"Clin Ther"},{"key":"R5-21-20210202","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"key":"R8-21-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4690-6-27","article-title":"The Spanish HIV BioBank: a model of cooperative HIV research.","volume":"6","author":"Garcia-Merino","year":"2009","journal-title":"Retrovirology"},{"key":"R9-21-20210202","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/JCM.01613-06","article-title":"Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1).","volume":"45","author":"Rodes","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R10-21-20210202","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/QAD.0b013e32830c481b","article-title":"Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.","volume":"22","author":"Salazar","year":"2008","journal-title":"AIDS"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e3181d285ac","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:28:17Z","timestamp":1620955697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201006000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3181d285ac","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}